from Q2 2010 to Q2 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary: ELITE PHARMACEUTICALS INC /NV/ quarterly and annual Net Cash Provided by (Used in) Financing Activities history and change rate from Q2 2010 to Q2 2025.
ELITE PHARMACEUTICALS INC /NV/ Net Cash Provided by (Used in) Financing Activities for the quarter ending 30 Jun 2025 was $4,130,684, a 2262% decline year-over-year.
ELITE PHARMACEUTICALS INC /NV/ annual Net Cash Provided by (Used in) Financing Activities for 2024 was $825,740, a 125% decline from 2023.
ELITE PHARMACEUTICALS INC /NV/ annual Net Cash Provided by (Used in) Financing Activities for 2023 was $3,339,181, a 96% increase from 2022.
ELITE PHARMACEUTICALS INC /NV/ annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1,702,199.
Source SEC data: View on sec.gov

Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)

Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

Net Cash Provided by (Used in) Financing Activities, Annual (USD)

Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q2 2025	$4,130,684	-$3,955,778	-2262%	01 Apr 2025	30 Jun 2025	10-Q	14 Aug 2025	2026	Q1
Q2 2024	$174,906	-$4,132,129	-104%	01 Apr 2024	30 Jun 2024	10-Q	14 Aug 2025	2026	Q1
Q2 2023	$3,957,223	-$7,939,241	-67%	01 Apr 2023	30 Jun 2023	10-Q	14 Aug 2024	2025	Q1
Q2 2022	$11,896,464	+$12,049,013		01 Apr 2022	30 Jun 2022	10-Q	14 Aug 2023	2024	Q1
Q2 2021	$152,549	-$963,953	-119%	01 Apr 2021	30 Jun 2021	10-Q	15 Aug 2022	2023	Q1
Q2 2020	$811,404	+$697,394	+612%	01 Apr 2020	30 Jun 2020	10-Q	16 Aug 2021	2022	Q1
Q2 2019	$114,010	-$240,213	-68%	01 Apr 2019	30 Jun 2019	10-Q	14 Aug 2020	2021	Q1
Q2 2018	$354,223	-$51,187	-13%	01 Apr 2018	30 Jun 2018	10-Q	09 Aug 2019	2020	Q1
Q2 2017	$405,410			01 Apr 2017	30 Jun 2017	10-Q	09 Aug 2018	2019	Q1
Q2 2013	$352,013	+$176,043	+100%	01 Apr 2013	30 Jun 2013	10-Q	14 Aug 2013	2013	Q1
Q2 2012	$175,970	+$179,510		01 Apr 2012	30 Jun 2012	10-Q	14 Aug 2013	2013	Q1
Q2 2011	$3,540	-$423	-14%	01 Apr 2011	30 Jun 2011	10-Q	14 Aug 2012	2012	Q1
Q2 2010	$3,117			01 Apr 2010	30 Jun 2010	10-Q/A	19 Aug 2011	2011	Q1

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$825,740	-$4,164,921	-125%	01 Apr 2024	31 Mar 2025	10-K	30 Jun 2025	2025	FY
2023	$3,339,181	+$1,636,982	+96%	01 Apr 2023	31 Mar 2024	10-K	30 Jun 2025	2025	FY
2022	$1,702,199	+$2,369,332		01 Apr 2022	31 Mar 2023	10-K	01 Jul 2024	2024	FY
2021	$667,133	+$202,696	+23%	01 Apr 2021	31 Mar 2022	10-K	29 Jun 2023	2023	FY
2020	$869,829	-$1,559,365	-226%	01 Apr 2020	31 Mar 2021	10-K	29 Jun 2022	2022	FY
2019	$689,536	-$877,319	-56%	01 Apr 2019	31 Mar 2020	10-K	14 Jun 2021	2021	FY
2018	$1,566,855	-$104,212	-6.2%	01 Apr 2018	31 Mar 2019	10-K	29 Jun 2020	2020	FY
2017	$1,671,067	-$6,400,284	-79%	01 Apr 2017	31 Mar 2018	10-K	21 Jun 2019	2019	FY
2016	$8,071,351	-$690,898	-7.9%	01 Apr 2016	31 Mar 2017	10-K	14 Jun 2018	2018	FY
2015	$8,762,249			01 Apr 2015	31 Mar 2016	10-K	14 Jun 2018	2018	FY
2012	$1,835,847	+$1,941,427		01 Apr 2012	31 Mar 2013	10-K	21 Jun 2013	2012	FY
2011	$105,580	-$1,154,974	-110%	01 Apr 2011	31 Mar 2012	10-K	21 Jun 2013	2012	FY
2010	$1,049,394			01 Apr 2010	31 Mar 2011	10-K	29 Jun 2012	2011	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.